Understanding Sabiá virus infections (Brazilian mammarenavirus)

Nastri, Ana Catharina de Seixas Santos; Duarte‐Neto, Amaro Nunes; Casadio, Luciana Vilas Boas; Souza, William Marciel de; Claro, Ingra Morales; Manuli, Erika R.; Selegatto, Glória; Salomão, Matias Chiarastelli; Fialkovitz, Gabriel; Taborda, Mariane; Almeida, Bianca Leal de; Magri, Marcello Mihailenko Chaves; Guedes, Ana Rubia; Neto, Lauro Vieira Perdigão; Sataki, Fatima Mitie; Guimarães, Thaís; Mendes-Corrêa, Maria Cássia; Tozetto‐Mendoza, Tânia Regina; Fumagalli, Marcílio Jorge; Ho, Yeh‐Li; Silva, Camila Alves Maia da; Coletti, Thaís M.; Jesus, Jaqueline Góes de; Romano, Camila Malta; Hill, Sarah C.; Pybus, Oliver G.; Pinho, João Renato Rebello; Ledesma, Felipe Lourenço; Casal, Yuri Reis; Kanamura, Cristina Takami; Araújo, Leonardo José Tadeu de; Ferreira, Camila Santos da Silva; Guerra, Juliana Mariotti; Figueiredo, Luíz Tadeu Moraes; Dolhnikoff, Marisa; Faria, Nuno Rodrigues; Sabino, Éster Cerdeira; Alves, Venâncio Avancini Ferreira; Levin, Anna S.

doi:10.1016/j.tmaid.2022.102351

Cited by 10 publications

(28 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NW arenaviruses include other non-pathogenic viruses, such as Pichinde virus (PICV) belonging to the Clade A group and human-pathogenic WWAV belonging to the Clade A/Rec (D). Recently, CHF cases were reported in Bolivia in 2019 [ 20 ], BzHF cases caused by a novel strain of SABV were also reported in Brazil in 2020 [ 21 ], and a seasonal epidemic of VHF was documented in Colombia in 2021 ( Figure 2 ) [ 22 ]. In addition, novel mammarenaviruses have been detected in rodents worldwide [ 13 , 23 ], but the pathogenic potential of these viruses for humans has not been verified.…”

Section: Classification and Distribution Of Arenavirusesmentioning

confidence: 99%

“…Even the vaccine for AHF, Candid#1, has not been approved by the FDA due to concerns about the risks of residual virulence and reversion to pathogenicity [ 55 , 56 , 57 ]. Given the recent cases of other severe arenavirus infections, such as the cases of CHF in Bolivia in 2019, BzHF in Brazil in 2020, and the seasonal epidemic of VHF in Colombia in 2021 [ 20 , 21 , 22 ] and the isolation of novel arenavirus species potentially harmful to humans [ 13 , 23 ], vaccines against such diseases should be developed.…”

Section: Arenavirus Vaccine Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine Candidates against Arenavirus Infections

et al. 2023

View full text Add to dashboard Cite

The viral family Arenaviridae contains several members that cause severe, and often lethal, diseases in humans. Several highly pathogenic arenaviruses are classified as Risk Group 4 agents and must be handled in the highest biological containment facility, biosafety level-4 (BSL-4). Vaccines and treatments are very limited for these pathogens. The development of vaccines is crucial for the establishment of countermeasures against highly pathogenic arenavirus infections. While several vaccine candidates have been investigated, there are currently no approved vaccines for arenavirus infection except for Candid#1, a live-attenuated Junin virus vaccine only licensed in Argentina. Current platforms under investigation for use include live-attenuated vaccines, recombinant virus-based vaccines, and recombinant proteins. We summarize here the recent updates of vaccine candidates against arenavirus infections.

show abstract

Section: Classification and Distribution Of Arenavirusesmentioning

confidence: 99%

Section: Arenavirus Vaccine Developmentmentioning

confidence: 99%

Vaccine Candidates against Arenavirus Infections

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Diagnosis of BHF is difficult, with non-existent diagnostic methods besides sequencing/PCR testing restricted to reference or research laboratories, and usually performed retrospectively. 3 Thus, most SABV cases may go unnoticed, and the possibility of SABV emergence constitutes a significant risk to human health.…”

Section: Introductionmentioning

confidence: 99%

“…15 In 1999, a natural infection case was reported in a rural worker, 4 and in 2019, two individuals aged 63 and 52 years succumbed to natural SABV infection. 3 The initial symptoms of SABV infection can include fever, headache, malaise, and myalgia (Figure 1(C)). As the infection progresses, patients may experience more severe symptoms, such as nausea, vomiting, diarrhea, abdominal pain, and a rash.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Structural and molecular biology of Sabiá virus

Bezerra,

Melo-Hanchuk,

Marques

2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Brazilian mammarenavirus, or Sabiá virus (SABV), is a New World (NW) arenavirus associated with fulminant hemorrhagic disease in humans and the sole biosafety level 4 microorganism ever isolated in Brazil. Since the isolation of SABV in the 1990s, studies on viral biology have been scarce, with no available countermeasures against SABV infection or disease. Here we provide a comprehensive review of SABV biology, including key aspects of SABV replication, and comparisons with related Old World and NW arenaviruses. SABV is most likely a rodent-borne virus, transmitted to humans, through exposure to urine and feces in peri-urban areas. Using protein structure prediction methods and alignments, we analyzed shared and unique features of SABV proteins (GPC, NP, Z, and L) that could be explored in search of therapeutic strategies, including repurposing intended application against arenaviruses. Highly conserved catalytic activities present in L protein could be targeted for broad-acting antiviral activity among arenaviruses, while protein-protein interactions, such as those between L and the matrix protein Z, have evolved in NW arenaviruses and should be specific to SABV. The nucleoprotein (NP) also shares targetable interaction interfaces with L and Z and exhibits exonuclease activity in the C-terminal domain, which may be involved in multiple aspects of SABV replication. Envelope glycoproteins GP1 and GP2 have been explored in the development of promising cross-reactive neutralizing antibodies and vaccines, some of which could be repurposed for SABV. GP1 remains a challenging target in SABV as evolutive pressures render it the most variable viral protein in terms of both sequence and structure, while antiviral strategies targeting the Z protein remain to be validated. In conclusion, the prediction and analysis of protein structures should revolutionize research on viruses such as SABV by facilitating the rational design of countermeasures while reducing dependence on sophisticated laboratory infrastructure for experimental validation.

show abstract

Les fièvres hémorragiques causées par les arénavirus : de récentes avancées vaccinales

Mateo,

Baize

2023

Med Sci (Paris)

View full text Add to dashboard Cite

Le développement de vaccins contre les arénavirus est un enjeu global. En effet, plusieurs milliers de personnes meurent chaque année de la fièvre de Lassa en Afrique occidentale et les virus Machupo, Guanarito ou Chapare continuent de ré-émerger en Amérique du Sud. Pourtant, il n’existe à ce jour aucun vaccin validé pour une utilisation dans l’espèce humaine pour lutter contre ces arénavirus. Dans cette synthèse, nous présentons les différents arénavirus causant des maladies mortelles chez l’espèce humaine et les principaux candidats vaccins développés au cours des dernières décennies contre ces virus. Nous décrivons plus particulièrement le vaccin rougeole-Lassa, premier vaccin contre la fièvre de Lassa à avoir été testé dans l’espèce humaine, et la plateforme MOPEVAC qui permet de générer avec succès des vaccins mono- ou multivalents contre potentiellement tous les arénavirus pathogènes connus.

show abstract

Understanding Sabiá virus infections (Brazilian mammarenavirus)

Cited by 10 publications

References 36 publications

Vaccine Candidates against Arenavirus Infections

Vaccine Candidates against Arenavirus Infections

Structural and molecular biology of Sabiá virus

Les fièvres hémorragiques causées par les arénavirus : de récentes avancées vaccinales

Contact Info

Product

Resources

About